Medical Marijuana, Inc.’s Investment, AXIM Biotech, Launches World’s First Cannabigerol (CBG) Clinical Trials on Psoriasis and Eczema

MJNA’s Cannabis-Based Drug Development R&D Plans Expand With AXIM Biotech’s Clinical Trials On Patent-Pending AX-1602 Including Cannabigerol (CBG)

SAN DIEGO, CA – May 17, 2016 — Medical Marijuana, Inc. (OTC: MJNA) is pleased to announce that its hemp biotech investment, AXIM Biotechnologies, Inc. (OTC: AXIM), has begun the world’s first human dermatological clinical trials on psoriasis (PsO) and atopic dermatitis (AD), commonly known as eczema, based on AXIM’s AX-1602 proprietary, patent-pending topical ointment formulation containing cannabigerol (CBG) and other cannabinoids. Conducting the clinical trials is a world- renowned dermatologist and specialist on psoriasis and atopic dermatitis, Dr. Marcus Meinardi, at The Maurits Clinics in The Hague, The Netherlands. Psoriasis and eczema are estimated to affect nearly 200 million people worldwide by 2024 with combined market estimates at $16 billion by 2022.

Cannabigerol (CBG) “The Stem Cell Cannabinoid”

A non-psychoactive cannabinoid found in the plant genus Cannabis, CBG has a broad range of biological efficacies. Found to act as a high affinity α2-adrenergic receptor agonist, moderate affinity 5-HT1A receptor antagonist, and low affinity CB1 receptor antagonist, CBG has also been found to have an anti-nausea and anti-emetic (anti-vomiting) effects. In addition, CBG has demonstrated an anti-inflammatory effect, has been shown to reduce pain, ease symptoms of psoriasis, act as an antibacterial agent and even slow the proliferation of tumor cells in vitro and in-vivo.

Psoriasis (PsO) is a chronic immune-mediated disease estimated to affect more than 125 million people worldwide. Although a number of treatment options exist for PsO, there continues to be significant unmet need on the market. The psoriasis market will grow to $10.4 billion by 2020.

Atopic dermatitis (AD), also known as eczema, is a type of inflammation of the skin (dermatitis). The Atopic Dermatitis – Epidemiology Forecast to 2024 reports 67,630,097 atopic dermatitis cases, and atopic dermatitis therapeutic sales in the nine major markets that are forecast to increase to $5.6 billion by 2022.

A world leader in cannabis-based drug development, AXIM® Biotech’s core belief is responsibility for environmental stewardship combined with development of innovative products to address current conditions with no known effective treatment including: Parkinson’ s disease, Alzheimer’ s disease/dementia, ADHD (attention deficit hyperactivity disorder), PTSD, autism, MS, spasticity, pain,  RLS (restless leg syndrome), glaucoma, IBD, IBS and Crohn’s disease.

AXIM® Biotech is a significant investment company for Medical Marijuana, Inc. MJNA Investment Holdings, LLC holds 14,943,650 shares of common stock and 500,000 shares of preferred stock in the cutting-edge biotechnology innovator.

Medical Marijuana, Inc. looks forward to updating the public and shareholders in the days ahead. For more information on Medical Marijuana, Inc. and the portfolio company brands that it promotes, visit the Company website.

About Medical Marijuana Inc.

The mission of Medical Marijuana, Inc. (OTC: MJNA) is to be the premier hemp industry innovator, leveraging our team of professionals to source, evaluate and purchase value-added companies and products, while allowing them to keep their integrity and entrepreneurial spirit. We strive to create awareness within our industry, develop environmentally-friendly, economically sustainable businesses, while increasing shareholder value.

For more information, please visit the company’s website at:


These statements have not been evaluated by the FDA and are not intended to diagnose, treat or cure any disease.


This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties and other factors, which may cause the actual results, performance or achievements of Medical Marijuana, Inc. to be materially different from the statements made herein.


Medical Marijuana Inc. does not sell or distribute any products that are in violation of the United States Controlled Substances Act (US.CSA). These companies do grow, sell, and distribute hemp- based products and are involved with the federally legal distribution of medical marijuana-based products within certain international markets. Cannabidiol is a natural constituent of hemp oil.